Novo Nordisk's Wegovy Pill Records Nearly 20,000 Prescriptions in First Week
I'm PortAI, I can summarize articles.
Novo Nordisk's new weight-loss pill, Wegovy, recorded 18,410 prescriptions in its first week in the U.S., according to IQVIA data. Analysts are monitoring its sales to assess Novo Nordisk's market share against Eli Lilly. The pill's oral format is expected to attract more consumers compared to previous injectable options. Guggenheim noted that Wegovy's prescription numbers are exceeding other GLP-1 launches. Novo Nordisk's stock has risen approximately 25% this year, driven by strong expectations for Wegovy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments